



Rec'd PCT/FTO 27 APR 2005
PCT/GB 2003 / 0 0 4 6 8 5



INVESTOR IN PEOPLE

BEST AVAILABLE COPY

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 28 NOV 2003

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Signed

Dated

18 November 2003

R. Mahoney

The
**Patent
Office**

1/77

Request for grant of a patent

Read the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

26 FEB 2003

LONDON

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Your reference

T1614PV

27FEB03 E788122-1 D02639
P01/7700 0.00-0304415.3

Patent application number
(The Patent Office will fill in this part)

0304415.3

26 FEB 2003

Full name, address and postcode of the or of each applicant (underline all surnames)

Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

Patents ADP number (if you know it)

00597799001 ✓

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

Title of the invention

Therapeutic agents

Name of your agent (if you have one)

Dr. J. Thompson

Address for service" in the United Kingdom, to which all correspondence should be sent including the postcode)

Merck & Co., Inc.
European Patent Department
Terlings Park
Eastwick Road
Harlow
Essex CM20 2QR

Patents ADP number (if you know it)

4392742002 ✓

If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority Application number
(if you know it)

Date of filing
(day/month/year)

If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day/month/year)

Is a statement of inventorship and of right to grant of a patent required in support of his request? (Answer 'Yes' if:

Yes

any applicant named in part 3 is not an inventor, or
there is an inventor who is not named as an
applicant, or
any named applicant is a corporate body.

See note (d))

Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form 0

Description 29

Claim(s) 0

Abstract 0

Drawing(s) 0

10. If you are also filing any of the following,
state how many against each item.

Priority documents -

Translations of priority documents -

Statement of inventorship and right
to grant of a patent (Patents Form 7/77) -

Request for preliminary examination
and search (Patents Form 9/77) -

Request for substantive examination
(Patents Form 10/77) -

Any other documents -
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

J. Thompson

Dr. J. Thompson

Date 26 February 2003

12. Name and daytime telephone number of
person to contact in the United Kingdom

Dr. J. Thompson

01279 440172

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

THERAPEUTIC AGENTS

The present invention relates to a class of substituted purinone derivatives and to their use in therapy. More particularly, this invention is concerned with purin-6-one analogues which are substituted in the 9-
5 position by a substituted phenyl ring. These compounds are ligands for GABA_A receptors and are therefore useful in the therapy of adverse neurological disorders.

Receptors for the major inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), are divided into two main classes: (1) GABA_A receptors, which are members of the ligand-gated ion channel superfamily; and (2) GABA_B receptors, which may be members of the G-protein linked receptor superfamily. Since the first cDNAs encoding individual GABA_A receptor subunits were cloned the number of known members of the
10 mammalian family has grown to include at least six α subunits, four β subunits, three γ subunits, one δ subunit, one ϵ subunit and two ρ subunits.

Although knowledge of the diversity of the GABA_A receptor gene family represents a huge step forward in our understanding of this ligand-gated ion channel, insight into the extent of subtype diversity is still at an
20 early stage. It has been indicated that an α subunit, a β subunit and a γ subunit constitute the minimum requirement for forming a fully functional GABA_A receptor expressed by transiently transfecting cDNAs into cells. As indicated above, δ , ϵ and ρ subunits also exist, but are
25 present only to a minor extent in GABA_A receptor populations.

Studies of receptor size and visualisation by electron microscopy conclude that, like other members of the ligand-gated ion channel family, the native GABA_A receptor exists in pentameric form. The selection of at least one α , one β and one γ subunit from a repertoire of seventeen allows
30 for the possible existence of more than 10,000 pentameric subunit combinations. Moreover, this calculation overlooks the additional

permutations that would be possible if the arrangement of subunits around the ion channel had no constraints (i.e. there could be 120 possible variants for a receptor composed of five different subunits).

Receptor subtype assemblies which do exist include, amongst many others, $\alpha 1\beta 2\gamma 2$, $\alpha 2\beta \gamma 1$, $\alpha 2\beta 2/3\gamma 2$, $\alpha 3\beta \gamma 2/3$, $\alpha 4\beta \delta$, $\alpha 5\beta 3\gamma 2/3$, $\alpha 6\beta \gamma 2$ and $\alpha 6\beta \delta$. Subtype assemblies containing an $\alpha 1$ subunit are present in most areas of the brain and are thought to account for over 40% of GABA_A receptors in the rat. Subtype assemblies containing $\alpha 2$ and $\alpha 3$ subunits respectively are thought to account for about 25% and 17% of GABA_A receptors in the rat. Subtype assemblies containing an $\alpha 5$ subunit are expressed predominantly in the hippocampus and cortex and are thought to represent about 4% of GABA_A receptors in the rat.

A characteristic property of all known GABA_A receptors is the presence of a number of modulatory sites, one of which is the benzodiazepine (BZ) binding site. The BZ binding site is the most explored of the GABA_A receptor modulatory sites, and is the site through which anxiolytic drugs such as diazepam and temazepam exert their effect. Before the cloning of the GABA_A receptor gene family, the benzodiazepine binding site was historically subdivided into two subtypes, BZ1 and BZ2, on the basis of radioligand binding studies. The BZ1 subtype has been shown to be pharmacologically equivalent to a GABA_A receptor comprising the $\alpha 1$ subunit in combination with a β subunit and $\gamma 2$. This is the most abundant GABA_A receptor subtype, and is believed to represent almost half of all GABA_A receptors in the brain.

Two other major populations are the $\alpha 2\beta \gamma 2$ and $\alpha 3\beta \gamma 2/3$ subtypes. Together these constitute approximately a further 35% of the total GABA_A receptor repertoire. Pharmacologically this combination appears to be equivalent to the BZ2 subtype as defined previously by radioligand binding, although the BZ2 subtype may also include certain $\alpha 5$ -containing subtype assemblies. The physiological role of these subtypes has hitherto

been unclear because no sufficiently selective agonists or antagonists were known.

5 It is now believed that agents acting as BZ agonists at $\alpha 1\beta\gamma 2$, $\alpha 2\beta\gamma 2$ or $\alpha 3\beta\gamma 2$ subtypes will possess desirable anxiolytic properties. Compounds which are modulators of the benzodiazepine binding site of the GABA_A receptor by acting as BZ agonists are referred to hereinafter as "GABA_A receptor agonists". The $\alpha 1$ -selective GABA_A receptor agonists alpidem and zolpidem are clinically prescribed as hypnotic agents, suggesting that at least some of the sedation associated with known anxiolytic drugs which
10 act at the BZ1 binding site is mediated through GABA_A receptors containing the $\alpha 1$ subunit. Accordingly, it is considered that GABA_A receptor agonists which interact more favourably with the $\alpha 2$ and/or $\alpha 3$ subunit than with $\alpha 1$ will be effective in the treatment of anxiety with a reduced propensity to cause sedation. Moreover, agents which are inverse
15 agonists of the $\alpha 5$ subunit are likely to be beneficial in enhancing cognition, for example in subjects suffering from dementing conditions such as Alzheimer's disease. Also, agents which are antagonists or inverse agonists at $\alpha 1$ might be employed to reverse sedation or hypnosis caused by $\alpha 1$ agonists.

20 The compounds of the present invention, being selective ligands for GABA_A receptors, are therefore of use in the treatment and/or prevention of a variety of disorders of the central nervous system. Such disorders include anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, animal and
25 other phobias including social phobias, obsessive-compulsive disorder, stress disorders including post-traumatic and acute stress disorder, and generalized or substance-induced anxiety disorder; neuroses; convulsions; migraine; depressive or bipolar disorders, for example single-episode or recurrent major depressive disorder, dysthymic disorder, bipolar I and
30 bipolar II manic disorders, and cyclothymic disorder; psychotic disorders including schizophrenia; neurodegeneration arising from cerebral

ischemia; attention deficit hyperactivity disorder; Tourette's syndrome; speech disorders, including stuttering; and disorders of circadian rhythm, e.g. in subjects suffering from the effects of jet lag or shift work.

5 Further disorders for which selective ligands for GABA_A receptors may be of benefit include pain and nociception; emesis, including acute, delayed and anticipatory emesis, in particular emesis induced by chemotherapy or radiation, as well as motion sickness, and post-operative nausea and vomiting; eating disorders including anorexia nervosa and bulimia nervosa; premenstrual syndrome; muscle spasm or spasticity, e.g.
10 in paraplegic patients; hearing disorders, including tinnitus and age-related hearing impairment; urinary incontinence; and the effects of substance abuse or dependency, including alcohol withdrawal. Selective ligands for GABA_A receptors may be beneficial in enhancing cognition, for example in subjects suffering from dementing conditions such as
15 Alzheimer's disease; and may also be effective as pre-medication prior to anaesthesia or minor procedures such as endoscopy, including gastric endoscopy.

In addition, the compounds in accordance with the present invention may be useful as radioligands in assays for detecting compounds
20 capable of binding to the human GABA_A receptor.

The present invention provides a class of purinone derivatives which possess desirable binding properties at various GABA_A receptor subtypes. The compounds in accordance with the present invention have good affinity as ligands for the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit of the
25 human GABA_A receptor. The compounds of this invention may interact more favourably with the $\alpha 2$ and/or $\alpha 3$ subunit than with the $\alpha 1$ subunit; and/or may interact more favourably with the $\alpha 5$ subunit than with the $\alpha 1$ subunit.


The compounds of the present invention are GABA_A receptor
30 subtype ligands having a binding affinity (K_i) for the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit, as measured in the assay described hereinbelow, of 200 nM or

less, typically of 100 nM or less, and ideally of 20 nM or less. The compounds in accordance with this invention may possess at least a 2-fold, suitably at least a 5-fold, and advantageously at least a 10-fold, selective affinity for the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit relative to the $\alpha 1$ subunit.

5 However, compounds which are not selective in terms of their binding affinity for the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit relative to the $\alpha 1$ subunit are also encompassed within the scope of the present invention; such compounds will desirably exhibit functional selectivity in terms of zero or weak (positive or negative) efficacy at the $\alpha 1$ subunit and (i) a full or

10 partial agonist profile at the $\alpha 2$ and/or $\alpha 3$ subunit, and/or (ii) an inverse agonist profile at the $\alpha 5$ subunit.

The present invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof:



(I)

wherein

- X¹ represents hydrogen, halogen, C₁₋₆ alkyl, trifluoromethyl or C₁₋₆ alkoxy;
- 20 X² represents hydrogen or halogen;
- Y represents a chemical bond, an oxygen atom, or a -NH- linkage;
- Z represents an optionally substituted aryl or heteroaryl group;
- R¹ represents hydrocarbon, a heterocyclic group, trifluoromethyl,
- 25 -SO₂R^a, -SO₂NR^aR^b, -COR^a, -CO₂R^a or -CONR^aR^b; and

R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group.

The aryl or heteroaryl group Z in the compounds of formula I above may be unsubstituted, or substituted by one or more substituents.

5 Typically, the group Z will be unsubstituted, or substituted by one or two substituents. Suitably, the group Z is unsubstituted or monosubstituted. Typical substituents on the group Z include halogen, cyano, nitro, C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, oxy, C_{1-6} alkylsulphonyl, amino, aminocarbonyl, formyl, C_{2-6} alkoxy carbonyl and $-CR^a=NOR^b$, wherein R^a and R^b are as defined above.

For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.

Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

The term "hydrocarbon" as used herein includes straight-chained, branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms, and conveniently up to 12 carbon atoms. Suitable hydrocarbon groups include C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl(C_{1-6})alkyl, indanyl, aryl and aryl(C_{1-6})alkyl.

The expression "a heterocyclic group" as used herein includes cyclic groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur. The heterocyclic group suitably contains up to 15 carbon atoms and conveniently up to 12 carbon atoms, and is preferably linked through carbon. Examples of suitable heterocyclic groups include C₃₋₇ heterocycloalkyl, C₃₋₇ heterocycloalkyl(C₁₋₆)alkyl, heteroaryl and heteroaryl(C₁₋₆)alkyl groups.

Suitable alkyl groups include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl, butyl and pentyl groups. Particular alkyl groups are methyl, ethyl, *n*-propyl, isopropyl, isobutyl, *tert*-butyl and 2,2-dimethylpropyl. Derived expressions such as "C₁₋₆ alkoxy", "C₁₋₆ alkylamino" and "C₁₋₆ alkylsulphonyl" are to be construed accordingly.

Suitable alkenyl groups include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl, allyl and dimethylallyl groups.

Suitable alkynyl groups include straight-chained and branched alkynyl groups containing from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.

Suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl.

Typical examples of C₃₋₇ cycloalkyl(C₁₋₆)alkyl groups include cyclopropylmethyl, cyclohexylmethyl and cyclohexylethyl.

Particular indanyl groups include indan-1-yl and indan-2-yl.

Particular aryl groups include phenyl and naphthyl, preferably phenyl.

Particular aryl(C₁₋₆)alkyl groups include benzyl, phenylethyl, phenylpropyl and naphthylmethyl.

Suitable heterocycloalkyl groups include azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl groups.

Suitable heteroaryl groups include pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, pyrazinyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl groups.

The expression "heteroaryl(C₁₋₆)alkyl" as used herein includes furylmethyl, furylethyl, thienylmethyl, thienylethyl, oxazolylmethyl, oxazolylethyl, thiazolylmethyl, thiazolylethyl, imidazolylmethyl, imidazolylethyl, oxadiazolylmethyl, oxadiazolylethyl, thiadiazolylmethyl, thiadiazolylethyl, triazolylmethyl, triazolylethyl, tetrazolylmethyl, tetrazolylethyl, pyridinylmethyl, pyridinylethyl, pyrimidinylmethyl, pyrazinylmethyl, quinolinylmethyl and isoquinolinylmethyl.

The hydrocarbon and heterocyclic groups may in turn be optionally substituted by one or more groups selected from C₁₋₆ alkyl, adamantyl, phenyl, halogen, C₁₋₆ haloalkyl, C₁₋₆ aminoalkyl, trifluoromethyl, hydroxy, C₁₋₆ alkoxy, aryloxy, keto, C₁₋₃ alkylenedioxy, nitro, cyano, carboxy, C₂₋₆ alkoxycarbonyl, C₂₋₆ alkoxycarbonyl(C₁₋₆)alkyl, C₂₋₆ alkylcarbonyloxy, arylcarbonyloxy, aminocarbonyloxy, C₂₋₆ alkylcarbonyl, arylcarbonyl, C₁₋₆ alkylthio, C₁₋₆ alkylsulphinyl, C₁₋₆ alkylsulphonyl, arylsulphonyl, -NR^vR^w, -NR^vCOR^w, -NR^vCO₂R^w, -NR^vSO₂R^w, -CH₂NR^vSO₂R^w, -NHCONR^vR^w, -CONR^vR^w, -SO₂NR^vR^w and -CH₂SO₂NR^vR^w, in which R^v and R^w independently represent hydrogen, C₁₋₆ alkyl, aryl or aryl(C₁₋₆)alkyl.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially fluoro or chloro.

Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.

Suitable values for the X¹ substituent include hydrogen, fluoro, chloro, methyl, trifluoromethyl and methoxy; in particular hydrogen or fluoro; and especially fluoro.

5 Typical values of X² include hydrogen and fluoro, especially hydrogen.

In a preferred embodiment, Y represents a chemical bond.

In another embodiment, Y represents an oxygen atom.

In a further embodiment, Y represents a -NH- linkage.

10 Selected values for the substituent Z include phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl, any of which groups may be optionally substituted by one or more substituents.

15 In one favoured embodiment, Z represents an optionally substituted phenyl group, in particular monosubstituted or disubstituted phenyl. In another favoured embodiment, Z represents optionally substituted pyridinyl, especially unsubstituted, monosubstituted or disubstituted pyridin-2-yl, pyridin-3-yl or pyridin-4-yl.

20 Examples of suitable substituents on the group Z include fluoro, chloro, cyano, nitro, methyl, hydroxy, methoxy, oxy, methanesulphonyl, amino, aminocarbonyl, formyl, methoxycarbonyl and -CH=NOH.

Examples of particular substituents on the group Z include fluoro and cyano.

25 Detailed values of Z include difluorophenyl, cyanophenyl, (cyano)(fluoro)phenyl, (chloro)(cyano)phenyl, nitrophenyl, methoxyphenyl, methanesulphonyl-phenyl, pyridinyl, fluoro-pyridinyl, difluoro-pyridinyl, (amino)(chloro)pyridinyl, cyano-pyridinyl, methyl-pyridinyl, hydroxy-pyridinyl, methoxy-pyridinyl, oxy-pyridinyl, aminocarbonyl-pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, cyano-thienyl, aminocarbonyl-thienyl, 30 formyl-thienyl, methoxycarbonyl-thienyl, thienyl-CH=NOH, thiazolyl,

isothiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl and methyl-tetrazolyl.

Specific values of Z include difluorophenyl, cyanophenyl, (cyano)(fluoro)phenyl, pyridinyl and fluoro-pyridinyl.

5 In one embodiment, Z represents cyanophenyl, especially 2-cyanophenyl.

Typically, R¹ represents hydrocarbon, a heterocyclic group, trifluoromethyl, -COR^a or -CO₂R^a.

10 Typical values of R^a include hydrogen and C₁₋₆ alkyl. Suitably, R^a represents hydrogen or methyl.

Typical values of R^b include hydrogen, C₁₋₆ alkyl, hydroxy(C₁₋₆)alkyl and di(C₁₋₆)alkylamino(C₁₋₆)alkyl. Suitably, R^b represents hydrogen, methyl, ethyl, hydroxyethyl or dimethylaminoethyl. Particular values of R^b include hydrogen, hydroxyethyl and dimethylaminoethyl, especially
15 hydrogen or dimethylaminoethyl.

Suitable values of R¹ include C₁₋₆ alkyl, halo(C₁₋₆)alkyl, dihalo(C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, dihydroxy(C₁₋₆)alkyl, C₁₋₆ alkoxy(C₁₋₆)alkyl, di(C₁₋₆)alkoxy(C₁₋₆)alkyl, cyano(C₁₋₆)alkyl, C₂₋₆ alkoxycarbonyl(C₁₋₆)alkyl, C₃₋₇ cycloalkyl, heteroaryl, C₁₋₆ alkyl-heteroaryl, heteroaryl(C₁₋₆)alkyl, trifluoromethyl, formyl, C₂₋₆ alkylcarbonyl and C₂₋₆ alkoxycarbonyl.
20


Representative values of R¹ include C₁₋₆ alkyl, halo(C₁₋₆)alkyl, dihalo(C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl and trifluoromethyl.

Individual values of R¹ include methyl, ethyl, fluoromethyl, difluoromethyl, methoxymethyl, dimethoxymethyl, hydroxyethyl
25 (especially 2-hydroxyethyl), fluoroethyl (especially 2-fluoroethyl), difluoroethyl (especially 2,2-difluoroethyl), dimethoxyethyl (especially 2,2-dimethoxyethyl), isopropyl, hydroxypropyl, dihydroxypropyl (especially 1,2-dihydroxyprop-2-yl), cyanopropyl, methoxycarbonylpropyl (especially 2-methoxycarbonylprop-2-yl), *tert*-butyl, hydroxybutyl (especially
30 1-hydroxy-2-methylprop-2-yl), cyclopropyl, pyridinyl, furyl, thienyl,

oxazolyl, methylthiazolyl, methyloxadiazolyl, imidazolylmethyl, triazolylmethyl, trifluoroethyl, formyl, acetyl and methoxycarbonyl.

In a first embodiment, R¹ represents methyl. In a second embodiment, R¹ represents ethyl. In a third embodiment, R¹ represents fluoroethyl (especially 2-fluoroethyl). In a fourth embodiment, R¹ represents difluoroethyl (especially 2,2-difluoroethyl).

A particular sub-class of compounds according to the invention is represented by the compounds of formula IIA, and pharmaceutically acceptable salts thereof:



wherein

Z is as defined above;

X¹¹ represents hydrogen, fluoro, chloro, methyl, trifluoromethyl or methoxy;

X¹² represents hydrogen or fluoro; and

R¹¹ represents C₁₋₆ alkyl, halo(C₁₋₆)alkyl, dihalo(C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, dihydroxy(C₁₋₆)alkyl, C₁₋₆ alkoxy(C₁₋₆)alkyl, di(C₁₋₆)alkoxy(C₁₋₆)alkyl, cyano(C₁₋₆)alkyl, C₂₋₆ alkoxycarbonyl(C₁₋₆)alkyl, C₃₋₇ cycloalkyl, heteroaryl, C₁₋₆ alkyl-heteroaryl, heteroaryl(C₁₋₆)alkyl, trifluoromethyl, formyl, C₂₋₆ alkylcarbonyl or C₂₋₆ alkoxycarbonyl.

Suitable values of X¹¹ include hydrogen and fluoro, especially fluoro.

In a favoured embodiment, X¹² represents hydrogen. In another embodiment, X¹² represents fluoro.

Where R¹¹ represents heteroaryl, this group is suitably pyridinyl, furyl, thienyl or oxazolyl.

Where R¹¹ represents C₁₋₆ alkyl-heteroaryl, this group is suitably methylthiazolyl (e.g. 2-methylthiazol-5-yl) or methyloxadiazolyl (e.g. 3-methyl-[1,2,4]oxadiazol-5-yl).


Where R¹¹ represents heteroaryl(C₁₋₆)alkyl, this group is suitably imidazolylmethyl or triazolylmethyl.

Representative values of R¹¹ include C₁₋₆ alkyl, halo(C₁₋₆)alkyl, dihalo(C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl and trifluoromethyl.

Individual values of R¹¹ include methyl, ethyl, fluoromethyl, difluoromethyl, methoxymethyl, dimethoxymethyl, hydroxyethyl (especially 2-hydroxyethyl), fluoroethyl (especially 2-fluoroethyl), difluoroethyl (especially 2,2-difluoroethyl), dimethoxyethyl (especially 2,2-dimethoxyethyl), isopropyl, hydroxypropyl, dihydroxypropyl (especially 1,2-dihydroxyprop-2-yl), cyanopropyl, methoxycarbonylpropyl (especially 2-methoxycarbonylprop-2-yl), *tert*-butyl, hydroxybutyl (especially 1-hydroxy-2-methylprop-2-yl), cyclopropyl, pyridinyl, furyl, thienyl, oxazolyl, methylthiazolyl, methyloxadiazolyl, imidazolylmethyl, triazolylmethyl, trifluoromethyl, formyl, acetyl and methoxycarbonyl.

In a first embodiment, R¹¹ represents methyl. In a second embodiment, R¹¹ represents ethyl. In a third embodiment, R¹¹ represents fluoroethyl (especially 2-fluoroethyl). In a fourth embodiment, R¹¹ represents difluoroethyl (especially 2,2-difluoroethyl).

One representative subset of the compounds of formula IIA above is represented by the compounds of formula IIB, and pharmaceutically acceptable salts thereof:



(IIB)


wherein X^{11} , X^{12} and R^{11} are as defined above; and

R^2 represents hydrogen or fluoro.

5 In one embodiment, R^2 is hydrogen.

In another embodiment, R^2 is fluoro, in which case the fluorine atom R^2 is favourably attached to the phenyl ring at the 4-, 5- or 6-position (relative to the cyano group at position 2).

10 Another representative subset of the compounds of formula IIA above is represented by the compounds of formula IIC, and pharmaceutically acceptable salts thereof:



(IIC)


15 wherein X^{11} , X^{12} and R^{11} are as defined above; and

R^3 represents hydrogen or fluoro.

In one embodiment, R³ is hydrogen.

In another embodiment, R³ is fluoro.

A further representative subset of the compounds of formula IIA
above is represented by the compounds of formula IID, and
5 pharmaceutically acceptable salts thereof:



(IID)

wherein X¹¹, X¹², R³ and R¹¹ are as defined above; and

10 R⁴ represents hydrogen or fluoro.

Suitably, R⁴ represents hydrogen.

In another embodiment, R⁴ represents fluoro.

Specific compounds within the scope of the present invention
include:

15 3'-(1-methyl-6-oxo-1,6-dihydropurin-9-yl)biphenyl-2-carbonitrile;
and pharmaceutically acceptable salts thereof.

Also provided by the present invention is a method for the
treatment and/or prevention of anxiety which comprises administering to
a patient in need of such treatment an effective amount of a compound of
20 formula I as defined above or a pharmaceutically acceptable salt thereof.

Further provided by the present invention is a method for the
treatment and/or prevention of convulsions (e.g. in a patient suffering from
epilepsy or a related disorder) which comprises administering to a patient

in need of such treatment an effective amount of a compound of formula I as defined above or a pharmaceutically acceptable salt thereof.

5 The binding affinity (K_i) of the compounds according to the present invention for the $\alpha 3$ subunit of the human GABA_A receptor is conveniently as measured in the assay described hereinbelow. The $\alpha 3$ subunit binding affinity (K_i) of the anxiolytic compounds of the invention is ideally 50 nM or less, preferably 10 nM or less, and more preferably 5 nM or less.

10 The anxiolytic compounds according to the present invention will ideally elicit at least a 40%, preferably at least a 50%, and more preferably at least a 60%, potentiation of the GABA EC₂₀ response in stably transfected recombinant cell lines expressing the $\alpha 3$ subunit of the human GABA_A receptor. Moreover, the compounds of the invention will ideally elicit at most a 30%, preferably at most a 20%, and more preferably at most a 10%, potentiation of the GABA EC₂₀ response in stably transfected
15 recombinant cell lines expressing the $\alpha 1$ subunit of the human GABA_A receptor.

The potentiation of the GABA EC₂₀ response in stably transfected cell lines expressing the $\alpha 3$ and $\alpha 1$ subunits of the human GABA_A receptor can conveniently be measured by procedures analogous to the protocol
20 described in Wafford *et al.*, *Mol. Pharmacol.*, 1996, 50, 670-678. The procedure will suitably be carried out utilising cultures of stably transfected eukaryotic cells, typically of stably transfected mouse Ltk-fibroblast cells.

25 The compounds according to the present invention may exhibit anxiolytic activity, as may be demonstrated by a positive response in the elevated plus maze and conditioned suppression of drinking tests (cf. Dawson *et al.*, *Psychopharmacology*, 1995, 121, 109-117). Moreover, the compounds of the invention are likely to be substantially non-sedating, as may be confirmed by an appropriate result obtained from the response
30 sensitivity (chain-pulling) test (cf. Bayley *et al.*, *J. Psychopharmacol.*, 1996, 10, 206-213).

The compounds according to the present invention may also exhibit anticonvulsant activity. This can be demonstrated by the ability to block pentylenetetrazole-induced seizures in rats and mice, following a protocol analogous to that described by Bristow *et al.* in *J. Pharmacol. Exp. Ther.*,
5 1996, 279, 492-501.

In another aspect, the present invention provides a method for the treatment and/or prevention of cognitive disorders, including dementing conditions such as Alzheimer's disease, which comprises administering to a patient in need of such treatment an effective amount of a compound of
10 formula I as defined above or a pharmaceutically acceptable salt thereof.

Cognition enhancement can be shown by testing the compounds in the Morris watermaze as reported by McNamara and Skelton, *Psychobiology*, 1993, 21, 101-108. Further details of relevant methodology are described in WO 96/25948.

15 Cognitive disorders for which the compounds of the present invention may be of benefit include delirium, dementia, amnesic disorders, and cognition deficits, including age-related memory deficits, due to traumatic injury, stroke, Parkinson's disease and Down Syndrome. Any of these conditions may be attributable to substance abuse or
20 withdrawal. Examples of dementia include dementia of the Alzheimer's type with early or late onset, and vascular dementia, any of which may be uncomplicated or accompanied by delirium, delusions or depressed mood; and dementia due to HIV disease, head trauma, Parkinson's disease or Creutzfeld-Jakob disease.

25 In order to elicit their behavioural effects, the compounds of the invention will ideally be brain-penetrant; in other words, these compounds will be capable of crossing the so-called "blood-brain barrier". Preferably, the compounds of the invention will be capable of exerting their beneficial therapeutic action following administration by the oral route.


30 The invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a

pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, 5 parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium 10 stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active 15 ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the 20 present invention. Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer 25 dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such 30 materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

In the treatment of neurological disorders, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day.

The compounds in accordance with the present invention may be prepared by a process which comprises reacting a compound of formula III:




(III)

wherein X¹, X², Y, Z and R¹ are as defined above; with formic acid.

The reaction is conveniently accomplished by stirring the reactants at an elevated temperature, typically at the reflux temperature of the reaction mixture.

The intermediates of formula III may be prepared by reduction of a compound of formula IV:




(IV)

wherein X^1 , X^2 , Y, Z and R^1 are as defined above.


5 The reduction is conveniently effected by treating compound IV with a reducing agent, e.g. tin(II) chloride, typically at an elevated temperature in a suitable solvent, for example a mixture of ethanol and tetrahydrofuran.

The intermediates of formula IV may be prepared by reacting a compound of formula V with a compound of formula VI:

10



(V)



(VI)


wherein X^1 , X^2 , Y, Z and R^1 are as defined above, and L^1 represents a suitable leaving group.

15 The leaving group L^1 is typically a halogen atom, e.g. chloro.

The reaction between compounds V and VI is conveniently effected by heating the reactants, to a temperature typically in the region of 90°C , in the presence of a base such as triethylamine, in a solvent such as dimethylsulfoxide.

20 In another procedure, the compounds according to the present invention in which Y represents a chemical bond may be prepared by a

process which comprises reacting a compound of formula VII with a compound of formula VIII:




wherein X¹, X², Z and R¹ are as defined above, L² represents a suitable leaving group, and M¹ represents a boronic acid moiety -B(OH)₂ or a cyclic ester thereof formed with an organic diol, e.g. pinacol, 1,3-propanediol or neopentyl glycol, or M¹ represents -Sn(Alk)₃ in which Alk represents a C₁₋₆ alkyl group, typically *n*-butyl; in the presence of a transition metal catalyst.

In the compounds of formula VII above, the leaving group L² is typically trifluoromethanesulfonyloxy (triflyloxy); or a halogen atom, e.g. bromo.

The transition metal catalyst of use in the reaction between compounds VII and VIII is suitably tetrakis(triphenylphosphine)-palladium(0). The reaction is conveniently carried out at an elevated temperature in a solvent such as *N,N*-dimethylacetamide, 1,2-dimethoxyethane, 1,4-dioxane or tetrahydrofuran, advantageously in the presence of potassium phosphate, copper(I) iodide, sodium carbonate or cesium carbonate. Alternatively, the transition metal catalyst employed may be tris(dibenzylideneacetone)dipalladium(0), in which case the reaction is conveniently effected at an elevated temperature in a solvent such as 1,4-dioxane, typically in the presence of tri-*tert*-butylphosphine and potassium phosphate.

Alternatively, the compounds according to the present invention in which Y represents a chemical bond may be prepared by a process which comprises reacting a compound of formula IX with a compound of formula X:

5




10

wherein X^1 , X^2 , Z, R^1 , L^2 and M^1 are as defined above; in the presence of a transition metal catalyst; under conditions analogous to those described above for the reaction between compounds VII and VIII.

In an additional procedure, the compounds according to the present invention in which Y represents an oxygen atom may be prepared by a process which comprises reacting a compound of formula X as defined above with a compound of formula XI:


15



wherein X^1 , X^2 and R^1 are as defined above.

The reaction is conveniently carried out under basic conditions, e.g. using sodium hydride in a solvent such as *N,N*-dimethylformamide, typically at an elevated temperature which may be in the region of 120°C.

5 In a further procedure, the compounds according to the present invention in which Y represents a -NH- linkage may be prepared by a process which comprises reacting a compound of formula X as defined above with a compound of formula XII:



10

wherein X¹, X² and R¹ are as defined above.

In relation to the reaction between compounds X and XII, the leaving group L² in the compounds of formula X may suitably represent fluoro.

15


The reaction between compounds X and XII is conveniently carried out by heating the reactants, typically at a temperature in the region of 120°C, in a solvent such as *N,N*-dimethylformamide.

Where M¹ in the intermediates of formula VIII and IX above represents a boronic acid moiety -B(OH)₂ or a cyclic ester thereof formed with pinacol or neopentyl glycol, the relevant compound VIII or IX may be prepared by reacting bis(pinacolato)diboron or bis(neopentyl glycolato)diborane respectively with a compound of formula X or VII as defined above; in the presence of a transition metal catalyst.

20 The transition metal catalyst of use in the reaction between
25 bis(pinacolato)diboron or bis(neopentyl glycolato)diborane and compound

X or VII is suitably dichloro[1,1'-bis(diphenylphosphino)ferrocene]-palladium(II). The reaction is conveniently carried out at an elevated temperature in a solvent such as 1,4-dioxane, optionally in admixture with dimethylsulfoxide, typically in the presence of 1,1'-bis(diphenylphosphino)ferrocene and/or potassium acetate.


The intermediates of formula VII above may be prepared by reacting a compound of formula XIII:



(XIII)

wherein X¹, X², R¹ and L² are as defined above; with formic acid; under conditions analogous to those described above for the reaction between compound III and formic acid.

The intermediates of formula XIII may be prepared by reaction of a compound of formula V as defined above with a compound of formula XIV:




(XIV)

wherein X¹, X² and L² are as defined above; under conditions analogous to those described above for the reaction between compounds V and VI; followed by reduction of the nitro group in the resulting compound, under

conditions analogous to those described above for the reduction of the nitro group in compound IV.


Where L^2 in the intermediates of formula VII above represents triflyloxy, the relevant compound VII may be prepared by reacting the appropriate compound of formula XI as defined above with triflic anhydride, typically in the presence of pyridine.

The intermediates of formula XI above may suitably be prepared from the appropriate methoxy-substituted precursor of formula XV:



wherein X^1 , X^2 and R^1 are as defined above; by treatment with boron tribromide, typically in chloroform or dichloromethane; or with hydrogen bromide, typically in acetic acid at reflux.

The intermediates of formula XII and XV above may be prepared by reacting a compound of formula V as defined above with the appropriate compound of formula XVI:



wherein X^1 and X^2 are as defined above, and Y^1 represents amino or methoxy; under conditions analogous to those described above for the reaction between compounds V and VI; followed by reduction of the nitro group in the resulting compound, under conditions analogous to those described above for the reduction of the nitro group in compound IV; followed by reaction of the product thereby obtained with formic acid, under conditions analogous to those described above for the reaction between compound III and formic acid.

The compounds according to the invention in which Y represents a chemical bond and Z represents pyrrol-1-yl may be prepared by reacting a compound of formula XII as defined above with 2,5-dimethoxy-tetrahydrofuran. The reaction is conveniently accomplished at an elevated temperature in a solvent such as acetic acid.

Where they are not commercially available, the starting materials of formula V, VI, X, XIV and XVI may be prepared by methods analogous to those described in the accompanying Examples, or by standard methods well known from the art.

It will be understood that any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula I by techniques known from the art. For example, a compound of formula I wherein R^1 represents $-C(O-Alk^1)_2R^a$ initially obtained, wherein Alk^1 is C_{1-6} alkyl, typically methyl or ethyl, may be converted into the corresponding compound of formula I wherein R^1 represents $-COR^a$ by hydrolysis with a mineral acid, typically aqueous hydrochloric acid. A compound of formula I wherein R^1 represents $-COR^a$ may be converted into the corresponding compound of formula I wherein R^1 represents $-CF_2R^a$ by treatment with DAST. A compound of formula I wherein R^1 represents $-COCH_3$ may be treated with thioacetamide in the presence of pyridinium tribromide to furnish the corresponding compound of formula I wherein R^1 represents 2-methylthiazol-5-yl. Moreover, a compound of formula I

wherein R¹ is formyl may be treated with (*p*-tolylsulfonyl)methyl isocyanide (TosMIC) in the presence of potassium carbonate to afford the corresponding compound of formula I wherein R¹ represents oxazol-5-yl. A compound of formula I wherein Z is substituted with methoxy may be
5 converted to the corresponding compound wherein Z is substituted with hydroxy by treatment with boron tribromide.

Where a mixture of products is obtained from any of the processes described above for the preparation of compounds according to the invention, the desired product can be separated therefrom at an
10 appropriate stage by conventional methods such as preparative HPLC; or column chromatography utilising, for example, silica and/or alumina in conjunction with an appropriate solvent system.

Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of
15 stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The novel compounds may, for example, be resolved into their component enantiomers by
20 standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-*p*-toluoyl-d-tartaric acid and/or (+)-di-*p*-toluoyl-l-tartaric acid, followed by fractional crystallization and regeneration of the free base. The novel compounds may also be resolved by formation of diastereomeric
25 esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional
30 protecting groups, such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene &

P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons, 3rd edition, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The following Example illustrates the preparation of compounds according to the invention.

The compounds in accordance with this invention potently inhibit the binding of [³H]-flumazenil to the benzodiazepine binding site of human GABA_A receptors containing the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit stably expressed in Ltk⁻ cells.

Reagents

- Phosphate buffered saline (PBS).
- Assay buffer: 10 mM KH₂PO₄, 100 mM KCl, pH 7.4 at room temperature.
- [³H]-Flumazenil (18 nM for $\alpha 1\beta 3\gamma 2$ cells; 18 nM for $\alpha 2\beta 3\gamma 2$ cells; 10 nM for $\alpha 3\beta 3\gamma 2$ cells; 10 nM for $\alpha 5\beta 3\gamma 2$ cells) in assay buffer.
- Flunitrazepam 100 μ M in assay buffer.
- Cells resuspended in assay buffer (1 tray to 10 ml).

Harvesting Cells

Supernatant is removed from cells. PBS (approximately 20 ml) is added. The cells are scraped and placed in a 50 ml centrifuge tube. The procedure is repeated with a further 10 ml of PBS to ensure that most of the cells are removed. The cells are pelleted by centrifuging for 20 min at 3000 rpm in a benchtop centrifuge, and then frozen if desired. The pellets are resuspended in 10 ml of buffer per tray (25 cm x 25 cm) of cells.

Assay

Can be carried out in deep 96-well plates or in tubes. Each tube contains:

- 300 μ l of assay buffer.

- 50 μ l of [3 H]-flumazenil (final concentration for $\alpha 1\beta 3\gamma 2$: 1.8 nM; for $\alpha 2\beta 3\gamma 2$: 1.8 nM; for $\alpha 3\beta 3\gamma 2$: 1.0 nM; for $\alpha 5\beta 3\gamma 2$: 1.0 nM).
- 50 μ l of buffer or solvent carrier (e.g. 10% DMSO) if compounds are dissolved in 10% DMSO (total); test compound or flunitrazepam (to determine non-specific binding), 10 μ M final concentration.
- 100 μ l of cells.

Assays are incubated for 1 hour at 40°C, then filtered using either a Tomtec or Brandel cell harvester onto GF/B filters followed by 3 x 3 ml washes with ice cold assay buffer. Filters are dried and counted by liquid scintillation counting. Expected values for total binding are 3000-4000 dpm for total counts and less than 200 dpm for non-specific binding if using liquid scintillation counting, or 1500-2000 dpm for total counts and less than 200 dpm for non-specific binding if counting with meltilex solid scintillant. Binding parameters are determined by non-linear least squares regression analysis, from which the inhibition constant K_i can be calculated for each test compound.

The compound of the accompanying Example was tested in the above assay, and was found to possess a K_i value for displacement of [3 H]-flumazenil from the $\alpha 2$ and/or $\alpha 3$ and/or $\alpha 5$ subunit of the human GABA_A receptor of 100 nM or less.

EXAMPLE 1


3'-(1-Methyl-6-oxo-1,6-dihydropurin-9-yl)biphenyl-2-carbonitrile

Sodium methoxide (2.70 g, 50.0 mmol) was added portionwise over 10 min to a 0°C suspension of 4,6-dichloro-5-nitropyrimidine (4.85 g, 25.0 mmol) in methanol (90 ml). On complete addition the mixture was stirred at 0°C for 2 h. The precipitate was filtered and the filtrate evaporated. The residue was suspended in isohexane and filtered. The filtrate was evaporated and the residue purified by flash column chromatography on silica, eluting with 5% ethyl acetate in isohexane. Collecting appropriate

fractions gave 4-chloro-6-methoxy-5-nitropyrimidine (3.50 g, 74%) as a white solid: δ_H (400 MHz, $CDCl_3$) 4.15 (3H, s), 8.65 (1H, s).

4-Chloro-6-methoxy-5-nitropyrimidine (3.50 g, 18.5 mmol) and 3'-aminobiphenyl-2-carbonitrile (prepared according to the procedure described in WO 02/38568) (3.23 g, 16.6 mmol) were dissolved in triethylamine (9.32 g, 92.3 mmol) and dimethylsulfoxide (10 ml) and heated at 90°C for 18 h. The mixture was allowed to cool to ambient temperature then poured onto water (150 ml) and extracted with ethyl acetate (2 x 300 ml). The organic fractions were combined, washed with water (3 x 75 ml) and brine (50 ml), dried over anhydrous sodium sulfate, filtered and evaporated to give a brown solid. The brown solid was triturated with diethyl ether (50 ml), filtered, washed with diethyl ether (2 x 10 ml) and left to air dry, which gave 3'-(1-methyl-5-nitro-6-oxo-1,6-dihydropyrimidin-4-ylamino)biphenyl-2-carbonitrile (2.24 g, 38%) as a yellow solid: δ_H (360 MHz, $CDCl_3$) 3.52 (3H, s), 7.45-7.57 (5H, m), 7.68 (1H, ddd, J 8, 8 and 1), 7.78-7.82 (2H, m), 8.04 (1H, s), 11.13 (1H, s).


3'-(1-Methyl-5-nitro-6-oxo-1,6-dihydropyrimidin-4-ylamino)-biphenyl-2-carbonitrile (100 mg, 0.28 mmol) was suspended in THF (5 ml) and ethanol (5 ml), tin(II) chloride (162 mg, 0.72 mmol) added and the mixture heated under reflux for 18 h. The solvent was evaporated and the residue suspended in formic acid (20 ml) and heated under reflux for 48 h. The mixture was allowed to cool to ambient temperature and the solvent evaporated. The residue was dissolved in dichloromethane and methanol and evaporated onto silica. The product was purified by flash column chromatography on the same, eluting with dichloromethane (+0.1% 0.880 ammonia) on a gradient of methanol (2-5%). Collecting appropriate fractions gave 3'-(1-methyl-6-oxo-1,6-dihydropurin-9-yl)biphenyl-2-carbonitrile (35 mg, 37%) as a white solid: δ_H (500 MHz, DMSO) 3.55 (3H, s), 7.65 (1H, dd, J 8 and 8), 7.72-7.79 (3H, m), 7.85 (1H, ddd, J 8, 8 and 1), 7.97 (1H, dd, J 8 and 1), 8.00-8.04 (2H, m), 8.45 (1H, s), 8.59 (1H, s); m/z (ES⁺) 328 (M⁺+H).



THIS PAGE BLANK (USPTO)

PCT Application

GB0304685



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.